Literature DB >> 29064634

The ISTH Bleeding Assessment Tool and the risk of future bleeding.

M R Fasulo1, E Biguzzi1, M Abbattista1, F Stufano1, M T Pagliari1, I Mancini1, M M Gorski1, A Cannavò1, M Corgiolu1, F Peyvandi1,2, F R Rosendaal3.   

Abstract

Essentials ISTH Bleeding Assessment Tool (ISTH-BAT) is used to assist the diagnosis of bleeding disorders. We examined whether the ISTH-BAT is capable of predicting the risk of future bleeding. 136 subjects were administered the ISTH-BAT and followed for up to four years. The ISTH-BAT score failed to predict the risk of future bleeding.
SUMMARY: Background The ISTH Bleeding Assessment Tool (ISTH-BAT) is a diagnostic tool used in subjects with suspected inherited bleeding disorders. Aim To evaluate whether the ISTH-BAT, applied at first work-up in a tertiary-care center, predicts the risk of subsequent bleeding events. Methods This was an observational cohort study including all consecutive subjects, of either sex and any age, referred between 2011 and 2015 because of a suspected bleeding disorder. The analysis was restricted to those with an ISTH-BAT score of ≥ 3. Incidence rates (IRs) of major bleeding (MB) and clinically relevant non-major bleeding (CRNMB) events were calculated as the number of events over accrued person-years. The main analysis was performed with Cox regression analysis, assessing an ISTH-BAT score of ≤ 5 versus a score of > 5, as well as the score as a continuous variable, and various covariates (sex, age, and presence/absence of a final diagnosis). Results One hundred and thirty-six subjects had a median ISTH-BAT score of 4 (range 3-18). Eleven subjects (8.1%) had a bleeding event during follow-up (one MB event; 10 CRNMB events). The overall IR of bleeding events per 100 person-years was 3.7 (95% confidence interval [CI] 1.8-6.6). No difference was observed between subjects with an ISTH-BAT score of ≤ 5 and those with a score of > 5 (hazard ratio [HR] 1.2, 95% CI 0.3-4.6). The results were similar when the ISTH-BAT score was considered as a continuous variable (HR 1.1, 95% CI 0.9-1.4). The IR of bleeding was increased in individuals with a diagnosis of a hemostatic defect (IR of 7.5 per 100 person-years; HR 3.0, 95% CI 0.8-11.8). Conclusions The ISTH-BAT does not identify patients at increased risk of future bleeding events.
© 2017 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  bleeding disorder; bleeding score; diagnosis; hemorrhage; risk assessment

Mesh:

Year:  2017        PMID: 29064634     DOI: 10.1111/jth.13883

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  9 in total

1.  Rivaroxaban in patients undergoing surgical mitral valve repair.

Authors:  Feridoun Noohi; Parham Sadeghipour; Sirous Kordrostami; Omid Shafe; Majid Maleki; Majid Kyavar; Hooman Bakhshandeh; Yousef Rezaei; Mehrad Rokni; Jamal Moosavi; Ahmad Amin; Ahmad Tashakori Beheshti; Saeid Hosseini
Journal:  J Thromb Thrombolysis       Date:  2020-04       Impact factor: 2.300

2.  Utility of International Society on Thrombosis and Hemostasis Bleeding Assessment Tool (ISTH-BAT) in Patients with Inherited Bleeding Disorders: A Cross-Sectional Study from Southern India.

Authors:  Pagadalu Lokababu Ambika; Debdatta Basu; Sukesh Chandran Nair; Rakhee Kar
Journal:  Indian J Hematol Blood Transfus       Date:  2021-04-15       Impact factor: 0.900

Review 3.  Inherited thrombocytopenias: history, advances and perspectives.

Authors:  Alan T Nurden; Paquita Nurden
Journal:  Haematologica       Date:  2020-06-11       Impact factor: 9.941

4.  Primary healthcare practitioners and patient blood management in Africa in the time of coronavirus disease 2019: Safeguarding the blood supply.

Authors:  Claire L Barrett
Journal:  Afr J Prim Health Care Fam Med       Date:  2020-05-21

Review 5.  Bleeding in Critically Ill Children-Review of Literature, Knowledge Gaps, and Suggestions for Future Investigation.

Authors:  Adi Avniel Aran; Oliver Karam; Marianne E Nellis
Journal:  Front Pediatr       Date:  2021-01-27       Impact factor: 3.418

Review 6.  Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia.

Authors:  José María Bastida; José Ramón Gonzalez-Porras; José Rivera; María Luisa Lozano
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

Review 7.  Endothelium, Platelets, and Coagulation Factors as the Three Vital Components for Diagnosing Bleeding Disorders: A Simplified Perspective with Clinical Relevance.

Authors:  Abhinav Bhattarai; Sangam Shah; Sara Bagherieh; Omid Mirmosayyeb; Sangharsha Thapa; Sandip Paudel; Pawan Gyawali; Pitambar Khanal
Journal:  Int J Clin Pract       Date:  2022-08-27       Impact factor: 3.149

8.  Comparison of the Warfarin Dosing and Outcomes in Hmong Versus East Asians Patients: Real-World Data From an Integrated Healthcare System.

Authors:  Boguang Sun; Pui Ying Yew; Ya-Feng Wen; Chih-Lin Chi; Robert J Straka
Journal:  Cureus       Date:  2022-09-07

9.  Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report.

Authors:  Francesco Rodeghiero; Ingrid Pabinger; Margaret Ragni; Rezan Abdul-Kadir; Erik Berntorp; Victor Blanchette; Imre Bodó; Alessandro Casini; Paolo Gresele; Riitta Lassila; Frank Leebeek; David Lillicrap; Diego Mezzano; Patrizia Noris; Alok Srivastava; Alberto Tosetto; Jerzy Windyga; Barbara Zieger; Mike Makris; Nigel Key
Journal:  Hemasphere       Date:  2019-09-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.